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ABSTRACT: 
Introduction: Patients with chronic kidney disease (CKD) and estimated glomerular filtration 
rate (eGFR) <30 ml/min/1.73m2 (corresponding to CKD stage G4+) comprise a minority of 
the overall CKD population but have the highest risk for adverse outcomes. Many CKD G4+ 
patients are older with multiple comorbidities, which may distort associations between risk 
factors and clinical outcomes.  
Methods: We undertook a meta-analysis of risk factors for kidney failure treated with kidney 
replacement therapy (KRT), cardiovascular disease (CVD) events, and death in participants 
with CKD G4+ from 28 cohorts (n=185,024) across the world who were part of the CKD 
Prognosis Consortium.   
Results: In the fully adjusted meta-analysis, risk factors associated with KRT were time-
varying CVD, male sex, black race, diabetes, lower eGFR, and higher albuminuria and 
systolic blood pressure. Age was associated with a lower risk of KRT (adjusted HR 0.74, 
95% CI 0.69-0.80) overall, and also in the subgroup of individuals below 65 years of age. 
The risk factors for CVD events included male sex, history of CVD, diabetes, lower eGFR, 
higher albuminuria, and the onset of KRT. Systolic blood pressure showed a U-shaped 
association with CVD events. Risk factors for mortality were similar to those for CVD events 
but also included smoking. Most risk factors had qualitatively consistent associations across 
cohorts.  
Conclusion: Traditional CVD risk factors are of prognostic value in individuals with an 
eGFR <30 ml/min/1.73m2, although the risk estimates vary for kidney and CVD outcomes. 
These results should encourage interventional studies on correcting risk factors in this high-
risk population.   
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INTRODUCTION: 
Chronic kidney disease (CKD) has a major impact on the affected individuals’ lives and 
carries an economic burden to societies.1 The prevalence of CKD Stage G3+ (estimated 
glomerular filtration rate [eGFR] <60 ml/min/1.73m2) varies substantially across the world; 
in the USA, between 4.8% – 11.8,2 in China, 1.1% - 3.8%,3 and in Europe, 1.0 – 5.9%.4 
Globally, the prevalence of CKD with severely decreased GFR (G4+, eGFR <30 
ml/min/1.73m2) is much lower (<0.5%). However, associated morbidity and mortality is 
higher among patients with CKD G4+,5 and less is known about relevant risk factors.  
Patients with CKD have an elevated risk of progressing to kidney failure requiring kidney 
replacement therapy (KRT), cardiovascular disease (CVD) events, and mortality, with higher 
risk at higher CKD stage.6,7 Traditional cardiovascular risk factors such as older age and male 
sex are associated with CVD and mortality in CKD stage G3+.8 In addition, lower eGFR and 
higher albuminuria are important risk factors for progression to KRT, all-cause and 
cardiovascular mortality.7 However, risk factors for KRT, CVD events, and mortality may 
not be the same in a population which has already progressed to CKD G4+. For example, 
some believe that high blood pressure may be less of a risk factor in CKD with severely 
decreased GFR. In addition, it is not known whether risk factors vary by age – a characteristic 
of particular interest, given that the majority of patients with CKD G4+ are over the age of 65 
years.9 A better understanding of factors associated with different outcomes may inform 
treatment strategies. 
Using 28 cohorts from across the world, we investigated the relative risk associations 
between traditional risk factors and adverse outcomes in CKD G4+. We hypothesized that 
traditional risk factors would be important in CKD G4+ and that older age would not 
significantly modify the relationship between risk factors and outcomes.  
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MATERIALS AND METHODS: 
Study population 
This study followed a call for participation in the KDIGO controversies conference in 
Barcelona (December, 2016) for evaluation and management of CKD with severely 
decreased GFR. Study cohorts were part of the Chronic Kidney Disease Prognosis 
Consortium (CKD-PC), a worldwide, collaborative network consisting of CKD cohorts with 
information on eGFR and albuminuria.10,11 The underlying selection criteria are provided in 
the Supplement (Appendix 1 and Supplemental Table S1). For this specific project, 28 
cohorts were selected, with inclusion criteria consisting of at least 500 individuals over the 
age of 18 years with an eGFR ≤30 ml/min/1.73m2 (CKD Stage G4+) at any visit. 
Furthermore, the cohorts had to have follow-up for both KRT and death pre and post ESRD 
and at least 50 events of each outcome. Time at risk began at the first visit in which eGFR 
was observed to be <30 ml/min/1.73 m2. 
Study variables 
The study variables are listed in Table 1. eGFR was estimated by the CKD-EPI equation 
using age, sex, race, and serum creatinine standardized according to isotope dilution mass 
spectrometry traceable (IDMS) methods.12 For cohorts where serum creatinine was not 
standardized, we reduced the serum creatinine by 5%.13 Albuminuria was recorded as the 
urinary albumin/creatinine or protein/creatinine ratio and converted to ACR as done 
previously.14 If these measurements were not available, we used dipstick proteinuria 
information. Diabetes mellitus was defined as the use of glucose lowering drugs, a fasting 
glucose ≥7.0 mmol/L or non-fasting glucose ≥ 11.1 mmol/L, hemoglobin A1c ≥6.5%, or self-
reported diabetes. Smoking status was recoded as current smoking versus not smoking. 
History of cardiovascular disease was defined as a previous diagnosis of myocardial 
infarction, percutaneous coronary intervention, bypass grafting, heart failure or stroke. 
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There were three major outcomes; kidney failure treated with KRT, CVD event and death. 
We also studied recurrent hospitalization events as a secondary outcome. The KRT outcome 
was defined as start of kidney replacement therapy and either actively ascertained or 
ascertained through linkages to registries or ICD-codes (Appendix 1). As for the CVD event, 
we accepted both fatal and non-fatal coronary heart disease, stroke and heart failure events 
occurring after enrollment in our cohort (Appendix 1). If fatal events were lacking, we did 
include non-fatal events. Note that any CVD event could occur also in individuals with a 
history of CVD at baseline, but only the first event after enrollment was quantified. A 
competing event such as death is treated as a censoring for both KRT and CVD. 
 
Statistical analysis 
Since the focus of our analysis was the risk relationship rather than the absolute risk of 
events, we used cause-specific hazards models for both KRT and CVD, and used Cox 
proportional hazards models for death. For the purpose of analyses, age was expressed per 10 
years older, and eGFR per 5 ml/min/1.73m2 lower. Albuminuria from the heterogeneous 
sources was referred to as urine ACR and log-transformed and scaled such that the 
coefficients reflect a 10-fold increase in ACR. Systolic blood pressure was modelled as a 
linear spline with a knot at 140 mmHg, based on review of the literature and exploratory data 
analysis in in-house cohorts, and expressed per 20 mmHg higher value. Race, sex, diabetes, 
smoking and history of CVD were dichotomized.  In addition to serving as an outcome in 
some of the analyses, KRT and CVD were also modeled as time-varying variables during 
follow-up for analyses of the CVD and KRT, respectively, as well as for mortality for both.  
For analyses of hospitalizations, recurrent events were counted during follow-up. We started 
by analyzing the risk relationships in each cohort individually by time-varying Cox 
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proportional hazards models. For analyses of KRT and CVD as outcomes, death was treated 
as a censoring event. For hospitalization, we used negative binomial regression. Multiple 
imputation was used for any missing data except for demographic variables (age, sex, race), 
eGFR, and outcomes. Meta-analyses were conducted separately for studies with information 
on all three outcomes and those with information on only KRT and death. Adjusted risk ratios 
were pooled through meta-analysis using the random effects model.15 The random effects 
meta-analysis assumes that the observed estimates may vary across cohorts because of a real 
difference in effect of the variables in each study, but also because of chance. This type of 
analysis uses a more conservative approach, downplays larger studies, and produces 
confidence intervals that are generally larger than the corresponding fixed effects. Between-
study heterogeneity was quantified by the I2 statistic but also assessed through visual 
inspection of the individual coefficients and their corresponding 95% intervals.16,17 All 
analyses were re-run stratified by age below or above 65 years. Meta-regressions were 
performed to explain any underlying heterogeneity of the risk factors, with investigated 
explanatory variables including region, cohort type, average cohort eGFR, average cohort 
ACR, proportion missing ACR, average cohort age, median follow-up time, average systolic 
blood pressure, and proportion of the cohort that were men, had diabetes, a history of CVD, 
and were current smokers. All analyses were done in Stata 14 MP (College Station, TX).  
RESULTS 
Study characteristics: 
There were 28 cohorts included in this study, with 185,024 participants with eGFR <30 
ml/min/1.73m2 from 30 different countries. There were19 cohorts which had information on 
all three of the outcomes of interest (KRT, CVD events, and death), and 9 cohorts which only 
had information on KRT and death. The characteristics of all 28 cohorts are presented in 
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Table 1. Overall, average age was 70 years (standard deviation [SD], 13), 69% were men, 
11% were black, 5.4% were Asian, 46% had diabetes, and 50% had a history of CVD. The 
mean eGFR was 24 ml/min/1.73 m2 (SD, 6) and median urine ACR was 48 mg/g 
(interquartile range, 38 to 112). Inclusion criteria and extended description of the 
participating cohorts, covariates, and outcomes are found in the Appendix 1 and 
Supplemental Table S1. Mean follow-up for the 28 cohorts was 3.3 years (SD, 2.8). 
Risk factors for kidney failure requiring KRT after eGFR 30 ml/min/1.73 m2 
The unadjusted incidence rates for KRT ranged from 17 to 302 events per 1000 person-years 
between the different cohorts (Supplemental Table S2). In total, there were 22,301 (12.1%) 
KRT events among 185,024 people. The meta-analyzed adjusted hazard ratios (HR) and 95% 
confidence intervals (CI) for the relationship between risk factors and onset of KRT in the 19 
cohorts with outcome information on KRT, CVD events, and death are presented in Table 2, 
column 1. The risk factors most strongly associated with KRT were male sex (HR 1.44, 95% 
CI: 1.34-1.55), black race (HR 1.49, 95% CI: 1.29-1.72), lower eGFR (HR 1.73 per 5 
ml/min/1.73 m2 lower, 95% CI: 1.58-1.90), higher urine ACR (HR 2.15 per 10-fold higher, 
95% CI: 1.87-2.48), and the occurrence of a CVD event during follow-up (HR 2.28, 95% CI: 
2.02-2.57).  Older age was associated with a lower risk of KRT (HR per 10 years older, 0.74, 
95% CI 0.69-0.80). The direction and size of the age association was qualitatively consistent 
across most cohorts (Figure 1A). Men had higher risk of KRT in all of the participating 19 
cohorts, although the point estimate varied to some degree (Figure 2A). The relationship 
between the presence of diabetes and KRT (excluding three cohorts that did not include 
persons with and without diabetes mellitus) was slightly weaker (HR 1.30, 95% CI: 1.14-
1.47), with diabetes observed as an independent, statistically significant risk factor in only 8 
of 16 cohorts (Supplemental Figure S1A). In meta-regression analyses, the heterogeneity in 
the association between diabetes and KRT was mainly explained by differences in cohorts 
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with respect to urine ACR, with a stronger effect size in cohorts with less albuminuria testing 
and lower ACR levels, as well as to a lesser extent by differences in age, systolic blood 
pressure and history of CVD between the different cohorts (Supplemental Figure S2). In 
sensitivity analysis, we compared risk coefficients from the meta-analysis when the analyses 
were extended to the full 28 cohorts with information on KRT and death; results were similar 
(Supplemental Table S3, column 1 versus Table 2, column 1). 
 
Risk factors for CVD events after eGFR 30 ml/min/1.73 m2 
The unadjusted incidence rate of a CVD event was highly variable between the cohorts, both 
before and after KRT. In total, there were 44,401 (28.6%) CVD events that occurred among 
155,014 people. In the fully adjusted model, the onset of KRT was among the most important 
risk factors for a subsequent CVD event (HR 1.39; 95% CI 1.15-1.68) (Table 2, column 2). 
Other important risk factors for a CVD event included a history of CVD, the presence of 
diabetes, as well as older age, male sex, higher ACR, and lower eGFR.  Systolic blood 
pressure showed a U-shaped association with CVD event risk. Each 20 mmHg higher blood 
pressure above 140 mmHg was associated with a 9% higher risk of CVD events, whereas a 
systolic blood pressure of 140 mmHg relative to 120mmHg was associated with an 11% 
lower risk of CVD event. The association between age and CVD was consistent in direction 
across all cohorts but one (Figure 1B). Associations between sex and CVD events were also 
relatively similar across cohorts (Figure 2B), and meta-regression analyses did not identify 
any cohort-level factors that explained underlying heterogeneity (Supplemental Figure S3). 
The presence of diabetes was a strong risk factor for CVD in all cohorts but one 
(Supplemental Figure S1B). 
Risk factors for mortality after eGFR 30 ml/min/1.73 m2 
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In total, there were 81,979 (44.3%) deaths among 185,024 people during follow-up. In the 19 
cohorts with all outcomes present, the development of a CVD event and the onset of KRT 
were both exceedingly strong risk factors for subsequent death (Table 2, column 3). Other 
risk factors for mortality included lower eGFR and higher urine ACR, as well as older age, 
male sex, history of previous CVD, and the presence of diabetes. Similar to its association 
with CVD events, systolic blood pressure was associated with death in a non-linear fashion 
with lower blood pressure below 140 mmHg being associated with death, and no association 
for higher blood pressure with death above 140 mmHg. Smoking was significantly associated 
with death (HR 1.37; 95% CI 1.25-1.50). The association between age and mortality was 
qualitatively similar across cohorts (Figure 1C). The associations of male sex and diabetes 
with mortality were weaker and not always consistent in direction across cohorts and showed 
more heterogeneity between the different cohorts (Figure 2C and Supplemental Figure 
S1C). Meta-regression of the association between male sex and mortality as well as diabetes 
and mortality did not show any particular cohort-level factor that explained the variation 
(Supplemental Figures S4 and S5). The relationship between the risk factors and mortality 
remained similar in the analysis with all 28 cohorts included (Supplemental Table S3, 
column 2 versus Table 2, column 3). 
Risk factors for hospitalization 
Out of the 8 cohorts with information on hospitalization rates, the unadjusted incidence of 
recurrent hospitalization ranged from 12 to 1524 per 1000 person-years pre-onset of kidney 
failure treated with KRT, and 26 to 2293 hospitalizations per 1000 person-years after KRT 
(Supplemental Table S4). In all cohorts, hospitalizations rates were higher after KRT was 
initiated. Risk factors for recurrent hospitalizations included history of CVD, lower systolic 
blood pressure below 140 mmHg and higher systolic blood pressure above 140 mmHg, 
higher urine ACR and lower eGFR; history of CVD and higher systolic blood pressure above 
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140 mmHg were also risk factors post-KRT of similar magnitude both before and after KRT 
(Supplemental Table S5).  
Effect modification of risk factors by age  
In general, the associations between risk factors and outcomes (KRT, CVD event, and death) 
were similar in subgroups of participants with an age below or above 65 years (Figure 3). 
However, for both KRT and CVD events, diabetes was a slightly stronger risk factor in the 
younger subgroup.  In contrast, male sex was a stronger risk factor for KRT in those >65 
years of age. Notably, age demonstrated significant associations with each outcome within 
both age strata. For example, older age was associated with a lower risk of KRT even among 
those with an age <65 years.  
DISCUSSION 
In this large meta-analysis, we studied risk factors for KRT, CVD, and death in 185,244 
people with stages 4-5 CKD. Traditional risk factors were of important prognostic value in 
this population, although associations varied by outcome of interest. Overall, the greatest 
explained variation was observed for KRT, mostly due to very strong risk relationships 
between eGFR, albuminuria and KRT. Lower eGFR and higher albuminuria were slightly 
weaker risk factors for CVD and mortality. Male sex, black race, presence of diabetes, and 
higher systolic blood pressure all increased the risk of KRT, while older age was associated 
with a lower risk of KRT. The risk factors for CVD and mortality were similar to those for 
KRT, although older age was also a risk factor and there was a non-linear association with 
systolic blood pressure. Smoking was significantly associated only with mortality. 
Importantly, we found that the onset of KRT or a CVD event in individuals with an eGFR 
<30 ml/min/1.73m2 was strongly associated with subsequent mortality. Risk factor 
associations were fairly consistent across 28 cohorts as well as subgroups of age.   
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Although nephrologists know that those with severely decreased GFR represent a high-risk 
population for adverse outcomes, it has been difficult to assess the benefits of risk factor 
modification at this stage. The presence of multiple comorbidities in this population may 
distort relationships between risk factors such as hypertension and clinical outcomes.18 Most 
previous studies examining risk factors for CKD outcomes have recruited patients with a 
wide spectrum of kidney function7,8,19,20 and patients who survive to develop CKD stage G4+ 
may experience different risk associations when compared to those who never progress. Yet, 
studies in CKD stage G4+ are limited due to the relative rarity of disease and paucity of CKD 
stage G4+ disease registries. The results of our large, consortium-wide analysis including 
185, 244 individuals are consistent with the existing literature evaluating traditional risk 
factors in much smaller, local cohorts of patients with severely decreased GFR.21-23 
Age was one variable that showed differences in the direction of associations with different 
outcomes. The protective association between older age and KRT has been shown in 
some21,22,24 but not all25 previous studies.  In our study, the age coefficient was consistently 
“protective” for the development of KRT across cohorts, as well as within subgroups of older 
and younger age. On the other hand, older age was a risk factor for CVD and death as would 
be expected. The apparent protective effect of age may be attributable to the competing event 
of death, but it may also be related to the rapidity of eGFR decline26 and the fact that starting 
KRT is a treatment option influenced by patient choice. Older adults may be more likely to 
choose conservative care or have negative attitudes toward dialysis treatment.27 Alternatively, 
age may influence the timing of dialysis.28 
Besides age, other demographic risk factors were also associated with adverse outcomes.  
Male sex was a risk factor for KRT, CVD events, and death in CKD stage G4+, similar to 
findings in the general population. Indeed, in contrast to reports that women have a higher 
prevalence of CKD stage G3,5 in our study population of CKD stage G4+, men were in the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
majority. Mechanisms for a more rapid GFR decline in men could be related to underlying 
differences in glomerular hemo-dynamics, activity of local cytokines, or mediated by effects 
of sex hormones.29-31 Other reasons for the lower KRT incidence among women are also 
possible, such as later initiation of KRT,32 lower awareness,33 and lower rates of referral to 
nephrology care.5 Black race was a risk factor for KRT but not CVD events or death. This 
finding is consistent with previous work showing that African Americans have between 2-4-
times higher incidence of KRT than people of other races and a higher odds of severely 
decreased GFR as compared to whites.34,35 Some of the risk for CKD progression may be 
attributable to the presence of Apolipoprotein-1 risk variants36 or sickle cell trait (inheritance 
of a single copy of the sickle mutation), both of which occur more often in people with 
African ancestry.37  
Traditional cardiovascular risk factors have been found to increase the risk of new onset 
CKD.38 In our analysis, the occurrence of a new CVD event during follow-up was associated 
with a more than two-fold increase in the risk of KRT. Similarly, after the initiation of KRT, 
the risk of both CVD events and death increased considerably. These results suggest that 
those who have a very high risk of CVD are likely to be the same individuals who also 
progress to require KRT and who are more likely to die.  
Diabetes is an established risk factor for KRT, CVD, and all-cause mortality in the general 
population.39,40 In the kidney failure risk equation, a KRT prediction tool for people with 
CKD stage G3-G5, diabetes was not a significant risk factor once albuminuria had been taken 
into account.8,41 In contrast, our analysis found diabetes to be an independent risk factor for 
KRT in patients with CKD stage G4+. One reason for this difference could be that many of 
the participants in our study lacked ACR measurements. Although we used imputation to 
estimate ACR levels, we found that the effect of diabetes was stronger in cohorts with more 
missing ACR and lower ACR measurements – two correlated factors at the cohort level and 
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more indicative of an administrative cohort setting. Non-proteinuric CKD in the context of 
type 2 diabetes is a recognised risk factor for KRT, although the mechanisms of progressive 
kidney damage may be different when compared to patients who have albuminuria.42 
Albuminuria itself remained an independent risk factor for all outcomes studied in this meta-
analysis. Increases in albuminuria were recently shown to be associated with both the future 
initiation of KRT and mortality, whereas decreases were inversely correlated with KRT.43  
Smoking has been linked to new onset CKD and KRT in the general population.34,44 Our 
results are consistent with the recently published Study of Heart And Renal Protection 
(SHARP) sub-analysis, which showed that cigarette smoking was associated with risk of 
death, but not KRT in people with CKD G3+.45 Thus, even though the risk for KRT 
associated with smoking may change over the course of the disease, the elevated risk for 
death remains, reinforcing the importance of offering smoking cessation advice to people 
with severely decreased GFR. Elevated systolic blood pressure >140 mmHg has been 
demonstrated to be a risk factor for CVD and has also been associated with progression to 
KRT in CKD stage G3+ (eGFR <30 ml/min/1.73m2).46 Our results show an independent 
association between systolic blood pressure and KRT after adjusting for albuminuria in 
people with more severely decreased GFR. This may indicate that achieving blood pressure 
targets are important also at later CKD stages. For CVD events and death, we observed a U-
shaped risk association with higher risks both below 120 mmHg and above 140 mmHg. 
These results could be regarded as contradictive of some recent reports, suggesting better 
outcomes with intense blood pressure lowering medication.47 However, a more likely 
explanation is that our risk association for a low systolic blood pressure was confounded by 
comorbid factors, for example, patients with severe heart failure often having low, rather than 
high blood pressure.18 We did not include body mass index (BMI) and LDL cholesterol in our 
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analyses. For LDL in particular, there were many cohorts with missing information. Initial 
analyses of the data available indicated only weak relationships for both BMI and LDL.  
This is the largest analysis of risk factors for adverse outcomes in people with severely 
decreased GFR conducted so far and complements projections of the probability and timing 
of events.48 We have included studies from many different regions of the world and, by doing 
so, have increased the generalizability of our results. There has been a concern that people 
progressing to later CKD stages have a different risk profile compared with people earlier in 
the course of the disease. By focusing on this specific group we have found that many of the 
traditional risk factors remain predictive, but that some risk factors, like age, behave 
differently for the different outcomes. One limitation of our analysis is that the selection of 
study participants differed between the individual cohorts; some research cohorts have 
specific inclusion and exclusion criteria (and two cohorts included only diabetics), while the 
large administrative databases do not. This may have affected the representativeness of study 
participants. In addition, in most cohorts, only a subset of the participants were selected (i.e., 
those with eGFR <30 ml/min/1.73 m2), a process designed to capture both people with 
prevalent disease as well as “progressors.” However, although the studies differed 
substantially in selection criteria and recruitment, the consistency in qualitative size and 
direction of our risk estimates throughout the different cohorts were reassuring. Other 
limitations included lack of data on LDL cholesterol in most cohorts. Although in preliminary 
analyses, LDL cholesterol was not a strong risk factor for any of the events of interest, the 
lack of association may be driven by survival bias and confounding by nutritional status. 
Lack of time-updated measurements prohibited us from analyzing any change in the direction 
of the risk factors closer to initiation of dialysis. .  
In summary, this large meta-analysis of people with severely decreased GFR shows that 
traditional risk factors such as male sex, black race, diabetes, lower eGFR, higher 
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albuminuria, smoking and higher systolic blood pressure remain important in CKD stage 
G4+. Furthermore, patients with CKD with severely decreased GFR who develop either CVD 
events or KRT have an even higher risk of mortality. These results should encourage 
healthcare professionals to assess traditional risk factors in individuals with stages 4-5 CKD 
and to offer interventions to reduce exposure to those that are modifiable. Future studies 
assessing the clinical benefits of such interventions should include this high-risk population.  
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Table 1. Participating studies and baseline characteristics 
Study N 
Death  
(pre/post-
ESRD) ESRD 
CVD 
 (pre/post-
ESRD) 
Follow-
up, yrs 
Age, 
yrs SBP eGFR ACR % Male 
% 
Black 
% 
History 
of CVD 
% 
Diabetes 
% 
Smoker 
AASK (USA) 622 
135 
 (85/50) 286 
38 
 (38/0) 4 (3) 
56 
(12) 
135 
(21) 25 (4) 
130 (34, 
488) 60% 100% 53% 1% 29% 
BC CKD (Canada) 9672 
4717  
(3305/1412) 3036   5 (3) 
71 
(13) 
137 
(23) 24 (5) 
225 (42, 
1233) 55% 0.41% 16% 50% 11% 
CanPREDDICT 
(Canada) 1739 
452  
(322/130) 435 
334 
 (286/48) 3 (2) 
69 
(13) 
134 
(20) 23 (5) 
188 (37, 
929) 62% 1.6% 38% 52%   
CCF (USA) 9256 
3000  
(2640/360) 1115   2 (1) 
73 
(13) 
130 
(22) 24 (5) 
51 (13, 
346) 46% 17% 24% 30% 9% 
CRIB (UK) 315 
133 
 (62/71) 185   6 (3) 
62 
(14) 
152 
(23) 18 (7) 
589 (118, 
1345) 61% 5.1% 45% 17% 12% 
CRIC (USA) 1764 
473 
(235/238) 834 
475 
 (346/129) 5 (3) 
60 
(11) 
131 
(24) 25 (4) 
267 (48, 
1066) 54% 45% 45% 60% 14% 
CRISIS (UK) 1717 
710  
(553/157) 461   3 (3) 
66 
(14) 
140 
(22) 20 (6) 
150 (55, 
466) 62% 0.64% 48% 36% 14% 
GCKD (Germany) 504 
34  
(30/4) 33 
34 
 (32/2) 2 (0) 
64 
(11) 
140 
(22) 26 (4) 
130 (23, 
877) 61% 0% 43% 44% 15% 
Geisinger (USA) 19293 
10039  
(8953/1086) 1802 
6292  
(5822/470) 4 (4) 
73 
(14) 
127 
(22) 24 (5) 
48 (15, 
232) 41% 0.99% 56% 43% 6% 
GLOMMS2 (UK) 6384 
3283  
(3175/108) 265   3 (2) 
79 
(11)   25 (5) 
44 (10, 
189) 38% 0% 26% 12% 1% 
Gonryo (Japan) 729 
57  
(57/0) 354 
48  
(43/5) 2 (2) 
67 
(13) 
135 
(17) 19 (7) 
666 (318, 
1401) 59% 0% 27% 38%   
Hong Kong CKD 
groups 502 
191 
 (113/78) 270   6 (3) 
61 
(12) 
138 
(19) 17 (7) 
60 (21, 
150) 56% 0% 27% 46% 11% 
Maccabi (Israel) 12576 
7531  
(6800/731) 1693 
3480  
(3338/142) 4 (3) 
76 
(13) 
135 
(22) 25 (5) 
70 (10, 
301) 49% 0% 64% 46%   
MASTERPLAN 
(Netherlands) 437 
93 
 (58/35) 142 
32  
(30/2) 4 (1) 
61 
(12) 
138 
(22) 24 (5) 
185 (53, 
666) 69% 0% 32% 32% 18% 
MDRD (USA) 851 474  724   14 (7) 51 134 22 (6) 335 (64, 60% 10% 17% 9% 12% 
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(81/393) (13) (19) 1002) 
Nanjing CKD 
(China) 1584 
116  
(21/95) 1003 
108 
 (44/64) 4 (3) 
47 
(14) 
141 
(22) 21 (6) 
1008 (550, 
1839) 54% 0% 12% 21% 0.40% 
NephroTest 
(France) 740 
213  
(100/113) 372   6 (4) 
61 
(14) 
139 
(22) 22 (6) 
277 (69, 
820) 67% 11% 24% 36% 14% 
NRHP-URU 
(Uruguay) 2090 
658  
(505/153) 512 
385 
 (379/6) 3 (2) 
72 
(13) 
135 
(22) 21 (5) 83 (0, 655) 49% 0.14% 36% 32% 6% 
NZDCS (New 
Zealand) 1372 
919  
(576/343) 438 
620  
(545/75) 6 (3) 
71 
(12) 
138 
(21) 23 (6) 13 (2, 93) 43% 0.073% 47% 100% 9% 
PSP CKD (UK) 3522 
1251 
 (1224/27) 141 
688 
 (675/13) 2 (1) 
80 
(12) 
131 
(19) 24 (5) 
48 (18, 
151) 43% 0.51% 47% 30% 8% 
PSPA (France) 573 
437  
(238/199) 294   3 (2) 82 (5) 
145 
(22) 13 (4) 
463 (174, 
1015) 57% 0% 55% 39%   
RCAV (USA) 78114 
30012  
(28014/1998) 4148 
21672  
(21063/609) 3 (2) 
69 
(11) 
125 
(24) 24 (5) 
38 (10, 
220) 97% 21.56% 61% 58%   
RENAAL 
(Multi*) 1078 
234 
 (138/96) 327 
400  
(356/44) 3 (1) 60 (7) 
151 
(21) 26 (3) 
1604 (690, 
3133) 59% 12.52% 28% 100% 17% 
SCREAM 
(Sweden) 18486 
12370  
(11841/529) 1132 
7882  
(7709/165) 3 (2) 
70 
(12)   25 (5) 
112 (27, 
787) 45% 0% 54% 25%   
SMART 
(Netherlands) 137 
79 
 (55/24) 31 
29 
 (23/6) 6 (4) 
65 
(11) 
152 
(25) 21 (8) 
187 (47, 
523) 70% 0% 52% 29% 27% 
SRR CKD 
(Sweden) 2555 
778  
(532/246) 770 
912  
(807/105) 3 (2) 
69 
(14) 
142 
(23) 21 (6) 
211 (43, 
953) 66% 0% 33% 38%   
Sunnybrook 
(Canada) 1592 
636  
(457/179) 362 
533 
 (438/95) 3 (2) 
72 
(14) 
136 
(22) 23 (6) 
236 (62, 
807) 54% 0% 17% 41% 8% 
West of Scotland 
CKD (UK) 6820 
2954  
(2505/449) 1136 
419 
 (304/115) 5 (3) 
68 
(13) 
143 
(24) 24 (6) 
151 (34, 
800) 49% 0.088% 25% 21%   
Total 185024 81979 22301 44401                     
*RENAAL contains participants from 28 countries; Argentina, Austria, Brazil, Canada, Chile, China, Costa Rica, Czech Republic, Denmark, 
France, Germany, Hungary, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Peru, Portugal, Russia, Singapore, Spain, 
Slovakia, United Kingdom, United States of America, Venezuela 
All values are expressed as numbers unless other is indicated. Follow-up and age is presented in years (SD, standard deviation), Albumin 
creatinine ratio (ACR) in mg/g, estimated glomerular filtration rate (eGFR) by CKD-EPI equation in ml/min/1.73m2, Interquartile range (IQR), 
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Systolic blood pressure (SBP) in mmHg, cardiovascular disease (CVD), Diabetes mellitus (DM), Kidney failure treated with kidney replacement 
therapy (KRT). The selection criteria and extended information about each cohort is given in Appendix 1 and Table S1. 
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Table 2. Meta-analyzed hazard ratios of risk factors associated with KRT, CVD and Death in the 19 cohorts 
Hazard ratio (95% CI) 
Variables KRT CVD Death 
Age, 10 years 0.74 (0.69, 0.80) 1.30 (1.18, 1.44) 1.68 (1.61, 1.76) 
Male sex 1.44 (1.34, 1.55) 1.14 (1.08, 1.21) 1.14 (1.08, 1.21) 
Black 1.49 (1.29, 1.72) 1.02 (0.85, 1.23) 0.93 (0.82, 1.05) 
History of CVD 0.91 (0.82, 1.02) 2.57 (2.27, 2.92) 1.27 (1.18, 1.36) 
Smoker 1.02 (0.93, 1.11) 1.07 (0.99, 1.16) 1.37 (1.25, 1.50) 
SBP<140, 20mmHg 1.25 (1.10, 1.41) 0.90 (0.85, 0.95) 0.84 (0.81, 0.88) 
SBP≥140, 20mmHg 1.17 (1.10, 1.24) 1.09 (1.04, 1.15) 1.02 (0.97, 1.07) 
Diabetes Mellitus 1.30 (1.14, 1.47) 1.41 (1.30, 1.53) 1.12 (1.03, 1.22) 
eGFR, -5 ml/min/1.73m2 1.73 (1.58, 1.90) 1.07 (1.05, 1.10) 1.12 (1.09, 1.15) 
ACR, 2-fold increase 1.26 (1.21, 1.31) 1.05 (1.04, 1.07) 1.04 (1.02, 1.05) 
Time-varying CVD 2.28 (2.02, 2.57)   2.87 (2.57, 3.20) 
Time-varying KRT 
 
 1.39 (1.15, 1.68) 2.07 (1.80, 2.38) 
All values are expressed as pooled Hazard ratios with 95% confidence intervals. The HR for age is expressed for every 10 year increase in age at 
baseline, the HR for albumin to creatinine ratio (ACR) is expressed per two-fold increase in mg/g, the HR for estimated glomerular filtration rate 
(eGFR) is expressed for every 5 ml/min/1.73m2 decrease, the HR for systolic blood pressure (SBP) is expressed as per 20 mmHg increase in 
blood pressure above and below 140 mmHg. Other abbreviations include cardiovascular disease (CVD), Kidney failure treated with kidney 
replacement therapy (KRT). The three cohorts that did not include persons with and without diabetes mellitus did not contribute to the meta-
analyzed hazard ratio for Diabetes Mellitus. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
 
Figure 1. Variation of the age coefficient for KRT (A), CVD (B), and Death (C) across 19 cohorts in the main analysis 
   
The individual and average hazard ratios and 95% confidence interval from the adjusted cox regression model and expressed per 10 year higher 
age. Weights are from the random effects analysis. Heterogeneity between cohorts is assessed by I2. Kidney failure treated with kidney 
replacement therapy (KRT), cardiovascular disease (CVD). 
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Figure 2. Variation of the sex coefficient (male vs. female) for KRT (A), CVD (B), and Death (C) across 19 cohorts in the main analysis 
   
The individual and average hazard ratios and 95% confidence interval from the adjusted cox regression model. Weights are from the random 
effects analysis. Heterogeneity between cohorts is assessed by I2. Kidney failure treated with kidney replacement therapy (KRT), cardiovascular 
disease (CVD). 
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Figure 3. Risk Factor Modification by Age for KRT (A), CVD (B), Death (C) 
 
All values are expressed as hazard ratios (HR) and 95% confidence intervals unless other is 
indicated. The HR for age is expressed for every 10 year increase in age at baseline, the HR 
for albumin to creatinine ratio (ACR) is expressed per 2-fold increase in mg/g, the HR for 
estimated glomerular filtration rate (eGFR) is expressed for every 5 ml/min/1.73m2 decrease, 
the HR for systolic blood pressure (SBP) is expressed as per 20 mmHg increase in blood 
pressure above and below 140 mmHg. Albumin creatinine ratio (ACR) in mg/g, estimated 
glomerular filtration rate (eGFR), Systolic blood pressure (SBP) in mmHg, cardiovascular 
disease (CVD), History of CVD (HxCVD), Kidney failure treated with kidney replacement 
therapy (KRT). InCVD is a CVD event after study inclusion, inKRT is incident KRT. 
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